Ease of access initiative makes it easier to
qualify, also decreases the burden of medicinal cost for qualified
patients
MONCTON, NB, Jan. 23, 2019 /CNW/ - Organigram Holdings Inc.
(TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram
Inc. (the "Company" or "Organigram"), a leading licensed producer
of cannabis is pleased to announce it has made changes to its
compassionate care model by developing OrganiCare, a program
designed to improve access to medical cannabis for low-income
patients.
Effective immediately, patients who earn an annual income less
than $35,000 per year qualify for
OrganiCare, the Company's new program that offers qualified
patients a 30 per cent price reduction on all dried cannabis
products and oils.
Previously, compassionate pricing was offered to individuals
earning less than $30,000 per year
and offered a 25 per cent price reduction.
"We understand cost can be a barrier to medication for
patients," says Greg Engel, CEO,
Organigram. "It is important to us to do what we can to improve
access for patients who need it the most. It's our hope that
OrganiCare will allow a greater number of patients to access their
medicine."
Organigram's Compassionate Care Program was voted best in
Canada at the Canadian Cannabis
Awards in 2017.
"With this change, this support program solidifies Organigram's
position as the most accessible medical cannabis provider for
low-income Canadians," Engel says.
Patients who are already enrolled in the program need not
reapply. Patients who wish to apply for the first time must
validate their annual income with attestation documents from a
federal or provincial authority, including Canada Revenue Agency or
a disability support program. Information on how to apply can be
found at www.organigram.ca.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed
company whose wholly owned subsidiary, Organigram Inc., is a
licensed producer of cannabis and cannabis-derived products in
Canada.
Organigram is focused on producing the highest-quality,
indoor-grown cannabis for patients and adult recreational consumers
in Canada, as well as developing
international business partnerships to extend the company's global
footprint. Organigram has also developed a portfolio of legal adult
use recreational cannabis brands including The Edison Cannabis
Company, Ankr Organics, Trailer Park Buds and Trailblazer.
Organigram's primary facility is located in Moncton, New Brunswick and the Company is
regulated by the Cannabis Act and the Cannabis
Regulations (Canada).
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectations. Important factors that could cause actual results to
differ materially from the Company's expectations are disclosed in
the Company's documents filed from time to time on SEDAR (see
www.sedar.com). Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE OrganiGram